Comparative Pharmacology
Head-to-head clinical analysis: DETROL LA versus DICYCLOMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL LA versus DICYCLOMINE HYDROCHLORIDE.
DETROL LA vs DICYCLOMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
Competitive antagonist of muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses in the gastrointestinal tract, leading to smooth muscle relaxation.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
10-20 mg orally 3-4 times daily
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
1.8 to 2.5 hours (terminal half-life, shorter in younger patients)
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Renal (∼79.5% as unchanged drug and metabolites) with minor biliary/fecal elimination (∼8-10%)
Category C
Category A/B
Anticholinergic
Anticholinergic